Now is a crucial time for the gene therapy field, as the ripple effects of pioneering approvals in both the US and Europe are being felt globally, setting new benchmarks and posing unexpected questions.
Gene Therapy for Rare Disorders Europe is the uniquely focused conference that will bring the leaders in in this field together to discuss the critical factors involved in driving commercial success for gene therapies in the complex European landscape.
Bringing together leading experts from innovative biotechs, large pharma, payers, investors and academics, this conference will present a comprehensive insight into the cutting edge progress of gene therapies combatting rare disease.
Here’s a snapshot of the companies who attended last year:
Pfizer – Shire – Lysogene – BioMarin – Novasep – Horama – Orchard Therapeutics – Avrobio
Genzyme – Astellas – uniQure – Syneos Health – REGENXBIO – Chiesi – TIGET – Syncona
GenSight – GSK – Covance – Bioverativ – Cell Therapy Catapult – Vertex – DAK Gesundheit
MHRA – Vivet – Oxford Genetics – Innovate UK – Gilead – IQVIA – Servier – Rocket Pharma - Allergan Axovant Sciences – CombiGene – H3 Biomedicine – Johnson & Johnson – PTC Therapeutics
Sarepta Therapeutics – Locana – University of Pennsylvania - Sanofi
Join your colleagues and accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.
For more information, download the full event guide.